Reneuron Regulatory News (RENE)

For Immediate Release 9 January 2012

ReNeuron Group plc

("ReNeuron" or "the Company")

Notification of Stem Cell Technical Seminar: 17 January 2012

ReNeuron Group plc (AIM: RENE), a leading, UK-based stem cell company, is pleased to announce that it will host a Stem Cell Technical Seminar for analysts, investors and media on 17 January 2012.

ReNeuron is conducting the world's first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients; the PISCES study (Pilot Investigation of Stem Cells in Stroke). This study is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.

The study's lead investigator, Glasgow University's Professor Keith Muir, will discuss the progress of the study at the Seminar.

In addition, Professor Colin Blakemore from the University of Oxford will discuss the potential of stem cells as a new therapeutic approach to the treatment of a wide variety of medical conditions.

ReNeuron executives will also provide a technical insight into the Company and its product pipeline.

If you would like to attend the event, please contact Isabel Podda at Buchanan either via e-mail isabelp@buchanan.uk.com or via telephone on 020 74665000 ideally before Friday 13 January 2012. Places will be limited and there will be no admittance for individuals who have not confirmed their attendance in advance.

A detailed preliminary agenda for the seminar is shown below.

ReNeuron Stem Cell Technical Seminar: 17 January 2012

PRELIMINARY AGENDA

10.00-10.15 Registration and coffee

10.15-10.20 Introduction

Michael Hunt - Chief Executive Officer

10.20-10.30 Stem cells - their potential as a new therapeutic paradigm

Colin Blakemore FMedSciFRS - Professor of Neuroscience, Department of Physiology, Anatomy and Genetics, University of Oxford

10.30-10.40 Overview and advantages of ReNeuron's stem cell technologies

Dr John Sinden - Chief Scientific Officer

10.40-11.00 The PISCES clinical trial with ReN001 for stroke - a progress report

Keith Muir - SINAPSE Professor of Clinical Imaging and Consultant Neurologist, Institute of Neuroscience and Psychology, University of Glasgow

11.00-11.10 Coffee break

11.10-11.25 Clinical development of ReN001 and ReNeuron's other cell-based therapies - opportunities and challenges

Dr Mike McDonald - Clinical Development Consultant to ReNeuron

11.25-11.40 Manufacturing and scale-up of ReNeuron's cell-based therapies

Dr Kenny Pollock - Head of Cell Development

11.40-11.55 ReN009 for critical limb ischaemia - progress to date and future plans

Dr Paul Stroemer - Head of Pre-clinical Research

11.55-12.10 ReN003 for retinitis pigmentosa - progress to date and future plans

Dr John Sinden

12.10-12.30 Q&A

12.30-13.30 Buffet lunch

- Ends -

Enquiries:

Michael Hunt, Chief Executive Officer - ReNeuron +44 (0) 1483 302560

Dr John Sinden, Chief Scientific Officer - ReNeuron

Lisa Baderoon, Mark Court, Isabel Podda +44 (0) 20 7466 5000

Buchanan Communications

David Hart +44 (0) 20 7776 6550

Daniel Stewart & Company plc

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.